DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Thomas Jefferson University
Takeda
Massachusetts General Hospital
Janssen Research & Development, LLC
Massachusetts General Hospital
M.D. Anderson Cancer Center
Novartis
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fujifilm Pharmaceuticals U.S.A., Inc.
M.D. Anderson Cancer Center
Stemline Therapeutics, Inc.
Heinrich-Heine University, Duesseldorf
Takeda
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Kura Oncology, Inc.
Kirby Institute
M.D. Anderson Cancer Center
Arbeitsgemeinschaft medikamentoese Tumortherapie
Fred Hutchinson Cancer Center
Pfizer
M.D. Anderson Cancer Center
Universitätsklinikum Hamburg-Eppendorf
Nanexa AB
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Bristol-Myers Squibb
Rutgers, The State University of New Jersey
Prelude Therapeutics
M.D. Anderson Cancer Center
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
University of California, Davis
H. Lee Moffitt Cancer Center and Research Institute
Takeda
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute